2 employees
Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery.
2017
$54M
from 3 investors over 3 rounds
Gotham Therapeutics raised $54M on October 10, 2018
Investors: Forbion, Versant Ventures and S.R. One Ltd